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Abstract 34 
Objective 35 
Cigarette smoking is a major risk factor for bladder cancer (BC), however the impact of 36 
cigarette content remains unclear. This study aims to investigate tar, nicotine and carbon 37 
monoxide (TNCO) yields of different filtered cigarettes in relation to BC risk.    38 
Methods 39 
From the Bladder Cancer Prognosis Programme 575 non-muscle-invasive BC (NMIBC) 40 
cases, 139 muscle-invasive BC (MIBC) cases and 130 BC-free controls with retrospective 41 
data on smoking behaviour and cigarette brand were identified. Independently measured 42 
TNCO yields of cigarettes sold in the UK were obtained through the UK Department of 43 
Health and merged with the BCPP dataset to estimate daily intake of TNCO. 44 
Results 45 
BC risk increased by TNCO intake category for NMIBC cases (p for trend <0.050 in all 46 
multivariate models) but only for daily intake of tar for MIBC cases (p=0.046) in multivariate 47 
models. No difference in risk is observed between smokers of low tar/low nicotine and high 48 
tar/high nicotine cigarettes compared to never smokers, neither for NMIBC (p=0.544) nor 49 
MIBC (p=0.449).  50 
Conclusion 51 
High daily intake of TNCO additionally increases both NMIBC and MIBC risk compared to 52 
low daily intake. However since there is no difference in BC risk between low tar/low 53 
nicotine and high tar/high nicotine cigarette smokers it remains unclear whether smoking 54 
behaviour or TNCO yield of cigarettes explains this association.  55 
 56 
Keywords: urinary bladder neoplasms; smoking; epidemiology; toxicology  57 
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Background 58 
Bladder cancer (BC) ranks fifth in the list of most common cancers in Western countries and 59 
active smoking is indicated as its most common risk factor together with occupational 60 
exposure to carcinogenic chemicals and some diet-related factors (Al-Zalabani et al. 2016; 61 
Antoni et al. 2017). The impact of cigarette smoking has been quantified in a large number of 62 
studies, and a recent meta-analysis showed that current smokers have a three-fold increased 63 
risk of developing BC compared to never smokers (van Osch et al. 2016). 64 
 65 
The relation between the amount of smoking and cancer risk has been investigated 66 
extensively, and is mostly characterised by smoking duration in years, smoking intensity in 67 
cigarettes per day, or pack years (an amalgamation of duration and intensity). However, the 68 
type of cigarette or cigarette composition is taken into account less often. Therefore, the 69 
evidence on the impact of different types of cigarettes, with regard to the composition of the 70 
cigarette smoke, on BC risk remains weak. Previous studies have shown lower BC risks for 71 
filter versus non-filter cigarette smokers and also when comparing blond tobacco to black 72 
tobacco (Clavel et al. 1989; García-Closas et al. 2005; Howe et al. 1980; Vineis et al. 1984). 73 
Two observational studies quantified BC risk for different intakes of tar and nicotine, of 74 
which one showed a linearly increasing trend in risk related to the amount of tar and nicotine 75 
and the other study showed no association between BC risk and cumulative tar intake 76 
(Castelao et al. 2001; Zeegers et al. 2002). By introducing the filter tip, which changed 77 
cigarette design but not necessarily the contents, smoking-related mortality has moderately 78 
decreased (Tang et al. 1995), although there are studies indicating that the levels of 79 
carcinogens in contemporary cigarettes might have become higher (Baris et al. 2009). 80 
Nevertheless, it remains unclear whether differences in cigarette content are related to 81 
meaningful differences in BC risk at population level. Therefore, we calculated the levels of 82 
 4 
tar, nicotine and carbon monoxide (TNCO) in mainstream smoke in a UK-based cohort study 83 
and aimed to investigate whether these levels influence BC risk.  84 
 5 
Methods  85 
Study population 86 
This case-control study was conducted within the framework of the West Midlands Bladder 87 
Cancer Prognosis Programme (BCPP), an ongoing BC patient cohort study conducted in 88 
multiple centres in the West Midlands, United Kingdom. Further details of the BCPP are 89 
described elsewhere (Zeegers et al. 2010). In summary, the study population contained 1,544 90 
adult individuals who were referred to one of the participating urology centres because of 91 
symptoms indicative of BC (predominantly haematuria). Of these 1,544 individuals, there 92 
were 1008 patients diagnosed with non-muscle-invasive bladder cancers (NMIBC), 275 93 
muscle-invasive bladder cancer (MIBC) patients and 205 individuals were subsequently 94 
diagnosed as free from any form of cancer after histological tests at the urology clinic and 95 
selected as controls. Additionally, 57 patients were diagnosed with other primary cancers 96 
(e.g. prostate cancer) or had missing data on important staging data so could not be confirmed 97 
to have BC(Figure 1).  98 
Cases and controls whom did not provide data on cigarette brand and smoking status 99 
were excluded for analysis. Of the 205 potential controls, 130 had a clear specification of 100 
control status and provided data on smoking status and cigarette brand. Of these 130 controls, 101 
34 had benign papillomas, 25 a normal urothelium, 24 cystitis and 20 urothelial 102 
inflammation. In addition, for 27 BCPP participants in the control group, the urologist did not 103 
provide a description apart from “no bladder cancer present” (Figure 1). All participants 104 
received a baseline questionnaire including questions to assess demographic characteristics, 105 
occupation and retrospectively characterise smoking and dietary behaviour. 106 
  107 
 6 
TNCO data from the UK Department of Health 108 
In the UK, an approved and accredited laboratory appointed by the UK Department of Health 109 
periodically and independently analyses the yields of tar (T), nicotine (N) and carbon 110 
monoxide (CO) in smoke of random samples of cigarette brands sold in the UK according to 111 
the International Organisation for Standardisation (ISO) standards (Legislation UK 2002). 112 
This examination verifies the TNCO yields declared on cigarette packs by manufacturers and 113 
ensures that the TNCO yields of cigarettes on the UK market do not exceed the maximum 114 
allowed levels as set out in the relevant Tobacco regulation (10 mg/cig for tar, 1 mg/cig for 115 
nicotine and 10mg/cig for CO). This is a legal obligation in all Member States of the EU, and 116 
is set out in the UK in the Tobacco Products (Manufacture, Presentation, Presentation and 117 
Sale) (Safety) Regulations 2002 (Statutory Instrument 3041) (Legislation UK 2002). For tar, 118 
measurements were made in line with ISO 4387 and for nicotine and CO, ISO 10315 and ISO 119 
8454 were used respectively, with the accuracy of measurements determined by ISO 8243 120 
(International Organization for Standardization (ISO)).  121 
By combining these data with the filter cigarette brand(s) currently or previously 122 
smoked in BCPP and the number of cigarettes smoked per day, daily intake of TNCO was 123 
estimated. Intake is a proxy measure for absolute TNCO exposure, since it is an estimation of 124 
the amount of TNCO that reaches the lungs which is also influenced by smoking behaviour 125 
(e.g. puff volume and whether the cigarette is smoked completely). Patients who smoked 126 
brands which were not in the UK Department of Health database were either excluded (88 127 
out of 602, 15%) or the TNCO values were based on the original packaging as determined by 128 
the manufacturer (40 out of 602, 7%).  129 
  130 
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Statistical analysis 131 
From the BCPP questionnaire data daily TNCO intake was estimated through multiplying the 132 
amount of cigarettes smoked per day (smoking intensity) with the TNCO levels. Based on 133 
these TNCO levels, cigarettes were classified as either low tar/low nicotine (tar<9 134 
mg/cigarette, nicotine <0.9 mg/cigarette) or high tar/high nicotine (tar≥9 mg/cigarette, 135 
nicotine≥0.9 mg/cigarette). Odds ratios (OR) and 95% confidence intervals (CI) estimating 136 
BC risk were calculated using logistic regression models. Potentially confounding factors 137 
included in multivariate analyses were restricted to age, sex, and smoking duration. Ideally, 138 
smoking intensity would also be included as a possible confounder but this was not possible 139 
due to collinearity issues because smoking intensity is used to estimate daily TNCO intake. 140 
Furthermore, data on occupation was sparse in controls (n=2 for controls, n=186 for NMIBC 141 
cases) so occupational exposure could not be included as a covariate. Tests for linear dose-142 
response trends in ORs between TNCO intake categories were performed by comparing 143 
logistic regression models with categorical variables for TNCO intake to models with a 144 
continuous variable for TNCO intake by using likelihood-ratio (LR) tests.   145 
 8 
Results 146 
After exclusion of cases and controls in the analysis because of missing data on cigarette 147 
brand or the number of cigarettes smoked per day 575 NMIBC, 139 MIBC and 130 BC-free 148 
participants were included in the analysis. Figure 1 summarises the inclusion of participants 149 
for this case-control study recruited from the BCPP participants. Table 1 shows the baseline 150 
characteristics of the included NMIBC, MIBC and BC-free controls who were included in the 151 
analysis. 152 
 153 
Table 2 shows linearly increasing dose-response relationships between daily tar, nicotine and 154 
CO intake and NMIBC risk compared to never smokers in both adjusted and unadjusted 155 
models (p-values below 0.05 in all models). The adjusted logistic regression models show 156 
mitigated associations compared to the unadjusted model. The highest OR was observed in 157 
the highest intake category for tar (OR=3.00, 95%CI=1.36-6.63), although the 95% 158 
confidence interval was wide.  159 
The results were similar when looking at MIBC risk albeit the 95% confidence 160 
intervals were wider due to the smaller number of MIBC cases (Table 3). Furthermore, the 161 
only increasing trend in a multivariate model was observed for daily tar intake (p=0.046) 162 
where the highest OR was 2.88 (95% CI=1.10-7.55). 163 
Furthermore, there does not seem to be a meaningful difference in BC risk between 164 
smokers of low tar/low nicotine cigarettes and smokers of high tar/high nicotine cigarettes 165 
(p=0.544 for NMIBC and p=0.449 for MIBC). Additionally, smokers of low tar/low nicotine 166 
cigarettes did not smoke more filter cigarettes than high tar/high nicotine cigarette smokers 167 
on a daily basis (p=0.516, data not shown).  168 
 9 
Discussion 169 
This study is the first to investigate all TNCO levels from cigarettes in relation to BC risk 170 
within a single study sample. Our results confirm the findings of another study, indicating a 171 
linearly increasing dose-response relationship for daily tar and nicotine intake. Additionally, 172 
we showed a similar association with daily CO intake (Zeegers et al. 2002). Another study 173 
investigating cumulative tar intake did not show any association with BC risk (Castelao et al. 174 
2001). Our results indicate that especially the highest daily intake categories of TNCO values 175 
are associated with an increased risk of BC compared to the lower categories. Tar in cigarette 176 
smoke is associated with cancer risk because of its high concentration of polycyclic aromatic 177 
hydrocarbons (PAHs), oxidants and free radicals which all play an important role in inducing 178 
DNA damage, possibly leading up to carcinogenesis (IARC 2010; Van Schooten et al. 1997).  179 
The results might be driven by the number of cigarettes smoked and to a lesser extent 180 
by TNCO values of cigarettes, since we did not observe any meaningful differences in BC 181 
risk between smokers of low tar/low nicotine and high tar/high nicotine cigarettes. Although 182 
this analysis was underpowered because of the low number of controls smoking low tar/low 183 
nicotine cigarettes (n=7). Although smokers of low tar/low nicotine cigarettes did not smoke 184 
more cigarettes than high tar/high nicotine cigarette smokers, they might have altered their 185 
smoking behaviour (e.g. larger puff volume or more puffs) to increase nicotine intake 186 
(Scherer 1999), as has been observed in other studies. Our estimates of daily TNCO intake 187 
might be confounded by this compenstation behaviour but could not be corrected for as 188 
detailed smoking behaviour data was not collected. 189 
Furthermore, the controls were selected from the BCPP cohort in which all 190 
participants were under suspicion of bladder cancer at inclusion. Therefore, the control group 191 
included individuals with chronic urothelial inflammation (Michaud 2007) and benign 192 
papilloma (including some inverted papillomas) (Picozzi et al. 2013) which could be 193 
 10 
considered risk factors for BC development. Hence, the presented ORs are probably 194 
underestimated because the our control group is more similar to the case group than a 195 
hypothetical, completely healthy control group because of the presence of these risk factors.  196 
 197 
In conclusion, high daily intake of TNCO increases NMIBC risk compared to low daily 198 
intake. However, it remains unclear whether smoking behaviour or cigarette type causes this 199 
association. More research with larger sample sizes is needed to corroborate these results and 200 
to shed light on whether smoking behaviour outplays cigarette content in determining BC 201 
risk.  202 
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Figure 1. Flow chart of case and control selection from Bladder Cancer Prognosis 268 
Programme 269 
 270 
Table 1. Baseline characteristics of NMIBC cases, MIBC cases and BC-free controls  271 
 272 
 273 
Table 2. Adjusted and unadjusted odds ratios (OR) estimating NMIBC risk for daily 274 
tar, nicotine and CO intake and cigarette type comparing ever smokers to never 275 
smokers. 276 
 277 
 278 
Table 3. Adjusted and unadjusted odds ratios (OR) estimating MIBC risk for daily tar, 279 
nicotine and CO intake and cigarette type comparing ever smokers to never smokers. 280 
  281 
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Table 1. Baseline characteristics of NMIBC cases, MIBC cases and BC-free controls  282 
  NMIBC (n=575) 
MIBC  
(n=139) BC-free (n=130) 
Age at diagnosis (95% CI) 68.0 (67.1 - 68.8) 70.1 (68.2 - 71.9) 65.2 (63.0 - 67.5) 
Sex (M/F) 442/133 99/40 91/39 
Smoking status 
   Never 127 31 59 
Former 299 67 45 
Current 149 41 26 
 283 
 284 
  411 
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Table 2. Adjusted and unadjusted odds ratios (OR) estimating NMIBC risk for daily 412 
tar, nicotine and CO intake and cigarette type comparing ever smokers to never 413 
smokers. 414 
 415 
  Cases in cohort 
Controls in 
cohort 
OR (95% CI) 
crude 
OR (95% CI) 
multivariate 
adjusted 
model* 
Never smoker 127 59 1.00 (reference) 1.00 (reference) 
Ever smoker 448 71 2.93 (1.97-4.36) 2.14 (1.11-4.11) 
     Tar (mg/day) 
    <100 130 30 2.01 (1.22-3.33) 1.57 (0.78-3.15) 
100-<200 154 21 3.41 (1.96-5.91) 2.73 (1.23-6.03) 
>200 161 19 3.94 (2.23-6.94) 3.00 (1.36-6.63) 
p-value for linear trend 
  
<0.001 0.007 
     Nicotine (mg/day) 
    <5 70 18 1.81 (0.99-3.30) 1.48 (0.69-3.18) 
5-<10 93 16 2.70 (1.46-4.99) 2.02 (0.90-4.55) 
10-<15 113 15 3.50 (1.88-6.51) 2.71 (1.15-6.41) 
>15 169 21 3.74 (2.16-6.47) 2.85 (1.32-6.19) 
p-value for linear trend 
  
<0.001 0.030 
     CO (mg/day) 
    <50 68 16 1.97 (1.06-3.69) 1.62 (0.73-3.56) 
50-<100 71 14 2.36 (1.23-4.52) 1.69 (0.74-3.83) 
100-<150 103 14 3.42 (1.81-6.47) 2.76 (1.15-6.61) 
>150 203 26 3.63 (2.17-6.05) 2.75 (1.30-5.84) 
p-value for linear trend 
  
<0.001 0.034 
Ever smoker cigarette 
type 
    Low tar/low nicotine 52 7 3.45 (1.48-8.05) 2.80 (0.97-8.06) 
High tar/high nicotine 396 64 2.87 (1.91-4.32) 2.14 (1.11-4.12) 
p-value       0.667 0.544 
*adjusted for age, sex and smoking duration 
 416 
  417 
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Table 3. Adjusted and unadjusted odds ratios (OR) estimating MIBC risk for daily tar, 418 
nicotine and CO intake and cigarette type comparing ever smokers to never smokers. 419 
  Cases in cohort 
Controls in 
cohort 
OR (95% CI) 
crude 
OR (95% CI) 
multivariate 
adjusted 
model* 
Never smoker 31 59 1.00 (reference) 1.00 (reference) 
Ever smoker 108 71 2.90 (1.71-4.91) 1.82 (0.79-4.21) 
     Tar (mg/day) 
    <100 33 30 2.09 (1.08-4.04) 1.31 (0.52-3.28) 
100-<200 28 21 2.54 (1.24-5.18) 1.42 (0.51-3.99) 
>200 44 19 4.41 (2.21-8.80) 2.88 (1.10-7.55) 
p-value for linear trend 
  
>0.001 0.046 
     Nicotine (mg/day) 
    <5 19 18 1.89 (0.92-4.37) 1.30 (0.48-3.50) 
5-<10 19 16 2.26 (1.02-5.00) 1.26 (0.43-3.70) 
10-<15 19 15 2.41 (1.08-5.39) 1.34 (0.43-4.20) 
>15 48 21 4.35 (2.22-8.52) 2.75 (1.07-7.11) 
p-value for linear trend 
  
>0.001 0.105 
     CO (mg/day) 
    <50 18 16 2.14 (0.96-4.77) 1.40 (0.51-3.83) 
50-<100 17 14 2.31 (1.01-5.30) 1.19 (0.39-3.60) 
100-<150 12 14 1.63 (0.67-3.95) 0.96 (0.29-3.16) 
>150 58 26 4.25 (2.25-8.01) 2.60 (1.03-6.56) 
p-value for linear trend 
  
>0.001 0.061 
Ever smoker cigarette 
type 
    Low tar/low nicotine 13 7 3.53 (1.27-9.77) 2.69 (0.73-9.84) 
High tar/high nicotine 95 64 2.83 (1.64-4.84) 1.80 (0.77-4.18) 
p-value       0.265  0.449 
*adjusted for age, sex and smoking duration 
 420 
 421 
